Pure D2CUS

Mangoceuticals benchmarks

MGRX · United States

How Mangoceuticals runs its business, at a glance: $300K in revenue in the last 12 months (-35.6%), compared with 32 other pure D2C brands on growth, margins and marketing. 4 fiscal years since 2022 and 15 quarters from SEC filings.

Compare your brandSee peersFull history

Revenue, last 12 months$300K-35.6% on the year before · #180 of 180 by revenue
Growth-35.6%Below the pure D2C median
Gross margin52.9%Below the pure D2C median
Marketing208%Spends more than the pure D2C median
Operating margin-2794.4%Below the pure D2C median

Operating scorecard

The numbers that show how Mangoceuticals runs: what it keeps from each sale, what it spends to win customers, and what is left. Each card shows the trend and where Mangoceuticals ranks.

Revenue, last 12 months

$300K-35.6% on a year earlier

In USD, as reported, 12 months to 2026-09.

2022: $9K2023: $731K2024: $616K2025: $456K
20222025

#180 by revenue of 180 brands in the benchmark.

Revenue growth

-35.6%▼ 9.7 pts vs 2025

Revenue against the year before

2023: +8083.2% (peer median +1.5%)2024: -15.8% (peer median +1.2%)2025: -26% (peer median +3.1%)
2022peer median2025

Below the pure D2C median (+4.6%). Grows faster than 3% of all 174 brands.

Gross margin

52.9%▼ 2 pts vs 2025

Left of each sale after product and delivery costs

2022: 54.3% (peer median 55.1%)2023: 59% (peer median 56.1%)2024: 61.7% (peer median 61.4%)2025: 54.9% (peer median 59.6%)
2022peer median2025

Below the pure D2C median (59.8%). Higher margin than 54% of all 169 brands.

Marketing spend

208%▲ 27.5 pts vs 2025

Share of revenue spent on marketing and advertising

2022: 3947.4% (peer median 17.9%)2023: 286.7% (peer median 19.4%)2024: 240.1% (peer median 18.5%)2025: 180.4% (peer median 16.6%)
2022peer median2025

Spends more than the pure D2C median (18.4%). Spends more than 98% of all 144 brands.

Headroom

-155%▼ 29.5 pts vs 2025

Gross margin minus marketing: what is left for the team, rent and profit

2022: -3893.2% (peer median 32.8%)2023: -227.8% (peer median 34.1%)2024: -178.4% (peer median 36.8%)2025: -125.5% (peer median 39.2%)
2022peer median2025

Below the pure D2C median (37.7%). More headroom than 1% of all 137 brands.

Operating margin

-2794.4%▲ 1159.9 pts vs 2025

Profit from operations, before interest and tax

2022: -22279.7% (peer median -0.7%)2023: -1260.3% (peer median -4.7%)2024: -1294.4% (peer median -3.2%)2025: -3954.3% (peer median -2.2%)
2022peer median2025

Below the pure D2C median (-2.8%). More profitable than 0% of all 178 brands.

Mangoceuticals: 12 months to 2026-09. Trend lines: the last 4 fiscal years, dashed line the median pure D2C brand in the same year. Bars: where Mangoceuticals sits among all 180 brands, from lowest to highest.

Where every 100 of revenue goes

For every 100 Mangoceuticals takes in: what the products cost to make and deliver, what goes to marketing, what runs the company, and what is left as profit.

Product and deliveryMarketingTeam, rent and other costsOperating profitLoss (costs above revenue)

Mangoceuticals12 months to 2026-09
Pure D2C median32 brands
All brands median180 brands

Medians are worked out line by line, so their parts can add up to slightly more or less than 100. Product and delivery is revenue minus gross profit; how much shipping sits there differs by company.

Compare your brand

Type in your own numbers to see where you stand against Mangoceuticals, the median pure D2C brand, and all 180 brands.

Your last 12 months, as % of revenue. Nothing you type leaves this page.

Your numbers against Mangoceuticals and the pure D2C median
MetricYouMangoceuticalsGapPure D2CmedianAmong all brands
Revenue growth–-35.6%–+4.6%–
Gross margin–52.9%–59.8%–
Marketing spend–208%–18.4%–
Headroom–-155%–37.7%–
Operating margin–-2794.4%–-2.8%–

Mangoceuticals and its peers

Pure D2C brands of a similar size, side by side.

All pure D2C brands
Mangoceuticals and the closest pure D2C brands by revenue
BrandRevenueGrowthGross marginMarketingHeadroomOp. margin
Desenio GroupDSNO · Europe SEK 738M-13.6%84.9%33.4%51.5%-29.2%
MilibooALMLB · Europe €44M+13%60.8%11.9%48.9%+0.7%
Prenetics GlobalPRE · US $31M+40.8%50.3%––-157.2%
Sleep CycleSLEEP · Europe SEK 248M-5.2%–8.1%–+26.6%
HannunHAN · Europe €6.8M-6.1%46.4%19.1%27.3%-28.5%
Newton GolfNWTG · US $6M-14.2%49.2%76.5%-27.3%-135.3%
Kombinat KonopnyKMB · Europe PLN 5.4M+39.3%–––-32%
MangoceuticalsMGRX · US $300K-35.6%52.9%208%-155%-2794.4%
Pure D2C median32 brands+4.6%59.8%18.4%37.7%-2.8%

The 7 pure D2C brands closest to Mangoceuticals in revenue. Green: above the median, grey: below. Revenue in each company's own currency.

Revenue by year

Every fiscal year on record, in USD. Point at a bar for growth and margins.

FY 2022: revenue $9K, gross margin 54.3%, marketing 3947.4%, operating margin -22279.7% $9K 2022FY 2023: revenue $731K, +8083.2% on a year earlier, gross margin 59%, marketing 286.7%, operating margin -1260.3% $731K 2023FY 2024: revenue $616K, -15.8% on a year earlier, gross margin 61.7%, marketing 240.1%, operating margin -1294.4% $616K 2024FY 2025: revenue $456K, -26% on a year earlier, gross margin 54.9%, marketing 180.4%, operating margin -3954.3% $456K 2025
RevenueGross margin (0–100% scale)Marketing (0–100% scale)
Mangoceuticals by fiscal year
Fiscal yearRevenueGrowthGross marginMarketingOp. marginNet marginSource
2025ends 2025-12-31 $456K-26%54.9% 180.4%-3954.3%-4526.8% 10-K filed 2026-04-01
2024ends 2024-12-31 $616K-15.8%61.7% 240.1%-1294.4%-1413.6% 10-K filed 2026-04-01
2023ends 2023-12-31 $731K+8083.2%59% 286.7%-1260.3%-1259.4% 10-K filed 2025-03-20
2022ends 2022-12-31 $9K–54.3% 3947.4%-22279.7%-22352.1% 10-K filed 2024-04-01

Revenue and margins by quarter

The last 15 calendar quarters. Most companies only report Q4 inside their annual report, so Q4 is the full year minus the first three quarters.

Q1 2023: revenue $101K, gross margin 56.8%, marketing 282.3%, operating margin -2540.8% Q1 2023Q2 2023: revenue $141K, gross margin 61.7%, marketing 564.5%, operating margin -1623% Q3 2023: revenue $245K, gross margin 59%, marketing 293.9%, operating margin -734% Q3 2023Q4 2023: revenue $244K, gross margin 58.3%, marketing 120.9%, operating margin -1050.9% Q1 2024: revenue $214K, +112.6% on a year earlier, gross margin 68.8%, marketing 398.1%, operating margin -1105.9% Q1 2024Q2 2024: revenue $163K, +15.5% on a year earlier, gross margin 42.8%, marketing 140.5%, operating margin -1329.1% Q3 2024: revenue $133K, -45.6% on a year earlier, gross margin 62%, marketing 188.4%, operating margin -1318.2% Q3 2024Q4 2024: revenue $105K, -56.9% on a year earlier, gross margin 76.1%, marketing 138.4%, operating margin -1594% Q1 2025: revenue $109K, -48.9% on a year earlier, gross margin 56.8%, marketing 257.7%, operating margin -4186.8% Q1 2025Q2 2025: revenue $168K, +3% on a year earlier, gross margin 53.5%, marketing 153.6%, operating margin -3134% Q3 2025: revenue $84K, -36.8% on a year earlier, gross margin 60.4%, marketing 124.5%, operating margin -8617.6% Q3 2025Q4 2025: revenue $94K, -10.3% on a year earlier, gross margin 50.3%, marketing 188.6%, operating margin -983% Q1 2026: revenue $68K, -37.9% on a year earlier, gross margin 42.7%, marketing 138.6%, operating margin -4606.8% Q1 2026Q2 2026: revenue $69K, -59.1% on a year earlier, gross margin 64.3%, marketing 438.4%, operating margin -1502.5% Q3 2026: revenue $70K, -17.5% on a year earlier, gross margin 55.2%, marketing 74%, operating margin -4762% Q3 2026
RevenueGross margin (0–100% scale)Marketing (0–100% scale)
All 15 quarters
Mangoceuticals by quarter
QuarterRevenuevs year earlierGross marginMarketingOp. marginSource
Q3 2026 $70K-17.5%55.2% 74%-4762% 10-Q filed 2026-11-16
Q2 2026 $69K-59.1%64.3% 438.4%-1502.5% 10-Q filed 2026-08-13
Q1 2026 $68K-37.9%42.7% 138.6%-4606.8% 10-Q filed 2026-05-19
Q4 2025full year minus Q1–Q3 $94K-10.3%50.3% 188.6%-983% 10-K filed 2026-04-01
Q3 2025 $84K-36.8%60.4% 124.5%-8617.6% 10-Q filed 2025-11-14
Q2 2025 $168K+3%53.5% 153.6%-3134% 10-Q filed 2026-08-13
Q1 2025 $109K-48.9%56.8% 257.7%-4186.8% 10-Q filed 2026-05-19
Q4 2024full year minus Q1–Q3 $105K-56.9%76.1% 138.4%-1594% 10-K filed 2026-04-01
Q3 2024 $133K-45.6%62% 188.4%-1318.2% 10-Q filed 2025-11-14
Q2 2024 $163K+15.5%42.8% 140.5%-1329.1% 10-Q/A filed 2025-11-14
Q1 2024 $214K+112.6%68.8% 398.1%-1105.9% 10-Q filed 2025-05-15
Q4 2023full year minus Q1–Q3 $244K–58.3% 120.9%-1050.9% 10-K filed 2025-03-20
Q3 2023 $245K–59% 293.9%-734% 10-Q filed 2024-11-14
Q2 2023 $141K–61.7% 564.5%-1623% 10-Q filed 2024-08-14
Q1 2023 $101K–56.8% 282.3%-2540.8% 10-Q filed 2024-05-15

Sources

Every figure is from Mangoceuticals's SEC filings (XBRL data in its 10-K and 10-Q reports): all filings on SEC EDGAR. Each row above links to the filing it came from.

Marketing is whatever the company reports as marketing, advertising or selling and marketing, so definitions differ between companies. Rankings compare each brand's latest 12 months (US) or latest fiscal year (Europe).

All D2C benchmarks

From the team behind this directory

You've seen how Mangoceuticals does it. Now see how yours compares.

Bratrax connects to your Shopify store and ad accounts and shows you the numbers that decide whether you're making money: profit after ad spend and product costs, which channels bring customers who come back, and where your next dollar should go.

$1 first month · then $99/month flat · no contract

  • Revenue, ad spend, MER and profit for the whole store on one screen
  • Every order traced back to the campaign that brought it
  • New vs. returning customers, cohorts and lifetime value
  • Email campaigns and flows, with the revenue they drove
  • Ask questions in plain English with your own Claude